Research investigating cytochrome P450 2C8 (CYP2C8) as a drug metabolizing enzyme has gained momentum over the past few years. CYP2C8 is estimated to oxidatively metabolize about 5% of therapeutically prescribed drugs. It is polymorphically expressed and several single nucleotide polymorphisms (SNPs) have been identified with varying effects on the clearance of CYP2C8 substrates.
Introduction
The involvement of cytochrome P450 2C8 (CYP2C8) in the metabolic clearance of drugs, drug interactions and its pharmacogenetics has been increasingly more recognized in the last several years (Totah and Rettie, 2005, Niemi et al., 2003; Kirchheiner et al., 2006; Tornio et al., 2008) . CYP2C8 accounts for 7% of total microsomal CYP content of the liver (Shimada et al., 1994; Rendic and Di Carlo, 1997) and is estimated to be involved in the oxidative metabolism of at least 5% of therapeutically prescribed drugs such as: amodiaquine, amiodarone, cerivastatin, paclitaxel, repaglinide, pioglitazone, rosiglitazone, and verapamil. CYP2C8 is also involved in the endogenous metabolism of arachidonic acid and all-trans-retinoic acid to epoxyeicosatrienoic acids and 4-hydroxy-all-trans-retinoic acid, respectively (Zeldin et al., 1995 and McSorley and Daly, 2000) . CYP2C8 shares more common substrates with CYP3A4 than it does with CYP2C9 despite having 70% sequence homology and 80% sequence similarity to CYP2C9 (Totah and Rettie, 2005) . In addition, similar transcription factors including PXR, CAR and GR are involved in the induction of CYP2C8 and CYP3A4 isozymes (Bahadur et al., 2002 Raucy et al., 2002 Ferguson et al., 2005) .
There is conflicting data in the literature with regards to in vitro and in vivo metabolic effects of CYP2C8 single nucleotide polymorphisms (SNPs). For example, individuals with the CYP2C8*1/*3 or CYP2C8*3/*3 genotypes have increased clearance of CYP2C8 substrates like repaglinide, rosiglitazone and pioglitazone than the individuals with the CYP2C8*1/*1 genotype (Niemi et al., 2005; Kirchheiner et al., 2006; Tornio et al., 2008) . In contrast, in vitro experiments and some in vivo pharmacokinetic studies involving the CYP2C8*3 allele showed contradictory results (Dai et al., 2001; Bahadur et al., 2002; Parikh et al., 2007, Daily and Aquilante, 2009 ). Niemi et al. (Niemi et al., 2003) reported that the CYP2C8*4 allele did not influence the pharmacokinetics of repaglinide. Accordingly, the metabolic activity of CYP2C8 alleles is somewhat controversial though ostensibly these CYP2C8 variants may have altered protein expression and/or function. This article has not been copyedited and formatted. The final version may differ from this version. 
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There is limited characterization of hepatic CYP2C8 protein expression in individuals with different CYP2C8 genotypes. This information would be valuable for studies scaling metabolism from human liver microsomes to whole liver, to determine the relationship between genotype-phenotype and explain the interindividual variability in pharmacokinetics of various CYP2C8 substrates. In addition, data pertaining to CYP2C8 ontogeny or gender differences are lacking. To address some of these issues, we genotyped for CYP2C8*3 and CYP2C8*4 (the most common SNPs in Caucasians), evaluated CYP2C8 mRNA and protein expression and examined the effect of age and gender on CYP2C8 expression in 60 Caucasian human liver samples.
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Materials and Methods
The CYP2C8 primary antibody (rabbit antibody to human CYP2C8) was purchased from GeneTex, Inc. (San Antonio, TX). Secondary antibodies (IRDye 680 goat-anti-rabbit and IRDye 800CW goat-anti-mouse) and Odyssey blocking reagent was obtained from LI-COR Biosciences (Lincoln, NE).
Western blotting reagents and NuPAGE® Novex® Bis-Tris mini gels were purchased from Invitrogen (Carlsbad, CA). Immobilon-FL-PVDF transfer membrane was obtained from Millipore (Billerica, MA).
Recombinant CYP enzymes, cDNA-expressed human P450 reductase and human cytochrome b5 Human liver microsomes were prepared according to previously published protocols (Paine et al., 1997) .
Protein concentrations were determined by the method of Lowry et al. (1951) . The expression levels of CYP3A4 were determined previously (Lin et al., 2002 Quantitation of CYP2C8 mRNA. Total mRNA from human liver (n=55) was extracted and normalized to ~200 ng/uL. Using 750 ng total RNA, whole genome expression measurement was carried out using the Illumina HumanRef-8 v.2 Expression BeadChips according to the manufacturer's protocol.
All liver samples were measured in duplicate, with each sample and replicate randomized between processed batches of 24 arrays done on different days. Raw signal intensity measurements from each sample were processed using the Illumina BeadStudio software v.2.3.41 using the 'average' normalization function and replicate data from each liver was averaged to obtain a final value.
Protein Quantitation. Immunoquantitation of CYP2C8 in human liver samples (n=53) was performed by Western blot analysis as described by Lin et al. (2002) , with minor modifications. Briefly, 20 µg of liver microsomal protein was resolved on NuPAGE® Novex® Bis-Tris mini gels by electrophoresis and transferred simultaneously onto PVDF membranes. The membrane was blocked overnight with Odyssey blocking reagent, incubated with the primary anti-CYP2C8 antibody (1:10000 dilution) followed by the secondary antibody (1:15000 dilution). The imaging of the membrane was performed on the Odyssey Infrared Imaging Systems (Li-COR Biosciences).
Recombinant human CYP2C8 was used as the standard for the protein-calibration curve (0.312-1.25 pmol of CYP2C8). Standards and liver samples were run in duplicate. A selected liver sample (HL-105) served as a quality control sample and was added to each gel to control for the inter-day variation.
CYP2C8 protein levels in liver samples were quantified by comparing the unknown band image intensity to the appropriate standard curve using Odyssey version 2.1.12. The cross reactivity of the CYP2C8 antibody was examined with other CYPs (CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP2B6 and CYP2J2 
Results and Discussion
Liver samples from 60 Caucasian individuals were included in this study. The median age was 46 years (range: 7 to 70 years) with nearly equal distribution of male and female donors (29 and 31, respectively). The observed allelic frequencies for CYP2C8*1, CYP2C8*3 and CYP2C8*4 were 0.82, 0.14 and 0.04, respectively. The CYP2C8*3 allele frequency determined in this study was comparable to the frequency of 0.15 reported in White British and White Spanish Caucasians (Bahadur et al., 2002) . The CYP2C8 genotype frequencies are summarized in Table 1 .
To identify the influence of different CYP2C8 SNPs on CYP2C8 transcript, mRNA levels were quantified in the liver samples. CYP2C8 mRNA was abundant in all the livers. The mean absolute value for CYP2C8 mRNA for each genotype is presented in Figure 1A . Compared to livers with a CYP2C8*1/*1 genotype, mean mRNA levels of livers with CYP2C8*1/*3 or CYP2C8*1/*4 genotypes were comparable ( Figure 1A and Table 1 ). The interindividual variation for CYP2C8 mRNA levels was 44-fold in the liver samples. For the CYP2C8*3/*3 livers, the mean mRNA levels were 48% lower compared to the CYP2C8*1/*1 livers. However, the statistical significance of this reduction cannot be estimated due to small sample size (n = 2) CYP2C8 in the microsomal fractions of liver samples was detected as an immunoreactive band at 55 kDa using a commercially available CYP2C8-specific polyclonal antibody (Figure 2 ). The antibody used was specific to CYP2C8 and did not cross-react with any of the other recombinant CYP proteins tested (data not shown). The inter-day variation for the control liver sample (HL-105) was 17.2%.
CYP2C8 mRNA levels were poorly correlated to CYP2C8 protein levels (r = 0.48, p=0.0005), although Rodriguez et al. (Rodriguez et al., 2008) reported a stronger correlation in their liver samples (r = 0.62).
CYP2C8 protein was detected in all liver samples and CYP2C8 protein expression as a function of CYP2C8 genotypes is presented in the (Niemi et al, 2003) failed to see a difference in ibuprofen clearance in CYP2C8*1/*4 subjects (n=3) compared to CYP2C8*1/*1 subjects (n=19). However, this null result may be due to the fact that CYP2C8 may only play a minor role in the metabolism of ibuprofen as determined by more recent in vitro studies (Chang et al., 2008) .
The effects of age and gender on the CYP2C8 protein expression are shown in Figures 3A and   3B , respectively. The ages of the donors ranged from 7 to 70 years and had no observable effect on the expression of CYP2C8. Rodriguez et al. (Rodriguez et al., 2008 ) also reported similar findings that age did not alter CYP2C8 expression. With regard to the gender, the mean expression levels of CYP2C8 protein was comparable in females (34.3 ± 17.7, n=28) and males (27.7 ± 17.4, n=25, p=0.18) ( Figure 3B ). However, it seems that females have slightly higher (22%) expression than males. At the mRNA transcript levels, there was no difference between females (19965 ± 10463, n=28) and males (19680 ± 12186, n=27) . In these same set of livers, CYP3A4 expression in females is higher by 57% as compared to the males although there is high variability in overall expression between two groups. The mean ± SD CYP3A4 expression levels in females was 101.3 ± 82.2 (n=31) as compared to 57.5 ± 63.9
This article has not been copyedited and formatted. The final version may differ from this version. (n=29) in males (Lin et al., 2002) . Similar findings of 2-fold increased levels of CYP3A4 expression was reported in 44 female livers as compared to the 48 male livers (Wolbold et al., 2003) .
As shown in Table 2 , CYP2C8 mRNA expression was highly correlated with the mRNA levels of CYP2C9 (r = 0.88), CYP2C19 (r = 0.68) and CYP3A4 (r = 0.71), but not CYP2C18 (r = 0.11). Similar transcription factors (PXR, CAR and GR) are involved in the induction and possibly basal regulation of various CYP2C family members and CYP3A4 (Bahadur et al., 2002 Raucy et al., 2002 Ferguson et al., 2005) . Liver samples from individuals exposed to inducers (such as dexamethasone, phenytoin or phenobarbital) prior to organ procurement had 45% higher levels of CYP2C8 mRNA (p=0.034), though CYP2C8 protein levels were not significantly different (p=0.48) than those not exposed. Similar to the mRNA expression data, CYP2C8 protein correlated strongly with CYP3A4 protein expression (r = 0.74, p<0.0001). Interestingly, from the entire set of human livers, 17% (n= 9) of the livers show higher CYP2C8 protein levels than CYP3A4. This could complicate studies on drug-drug interactions where compounds of interest are both CYP2C8 and CYP3A4 substrates and under conditions where CYP3A4 is inhibited.
From the recent CYP identification studies, there is a large degree of overlapping substrate specificity between CYP2C8 and CYP3A4. These substrates are structurally diverse from various therapeutic classes. Substrates that are predominantly metabolized by CYP2C8 for which CYP3A4 contributes partially to their clearance are: paclitaxel (Sonnichsen et al., 1995) , cerivastatin (Boberg et al., 1997 , Muck, 2000 , repaglinide (Bidstrup et al., 2003) and rosiglitazone (manuscript in preparation).
CYP3A4 substrates for which CYP2C8 contributes in part to their metabolism include carbamazapine (Kerr et al., 1994) , verapamil (Tracy et al., 1999) , zopiclone (Becquemont et al., 1999) and buprenorphine (Chang et al., 2006) . Not surprisingly, the general features of the active site in the CYP2C8 model are similar to those found in the CYP3A4 crystal structure (Tanaka et al., 2004 ) allowing for similar substrate specificity. Furthermore, some substrates such as amiodarone, amitriptyline, quinine and triazolam, which are metabolized completely or in part by CYP3A, caused >50% inhibition of CYP2C8 activity at This article has not been copyedited and formatted. The final version may differ from this version. Figure 1A . CYP2C8 mRNA levels (absolute values) for liver samples with different genotypes (n=55).
The mRNA levels were determined as described under Materials and Methods. Figure 1B . CYP2C8 protein contents of liver samples with different genotypes (n=53). Genotype and microsomal CYP2C8 content were determined as described under Materials and Methods.
Data points for individual liver samples are the average result of at least two western blots. . CYP2C8 and CYP3A4 protein content is highly correlated in human liver samples. The samples were previously characterized for CYP3A4 protein content (Lin et al., 2002) . The Spearman rank order coefficient was significant. From the entire set of human livers, 9 out of 53 (17%) show higher CYP2C8 expression levels than CYP3A4 expression.
